This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Illumina Expands Product Portfolio To Support Oncology Clinical Research And Discovery

Illumina, Inc. (NASDAQ:ILMN) today announced new products that can be applied directly to the discovery and translation of genomic variation in blood and tissue associated with cancer. The expanded portfolio leverages the company’s industry-leading next-generation sequencing (NGS) and microarray scanning systems to deliver sample-to-data solutions for basic and clinical cancer research.

New Product Additions

The following products complement the company’s existing NGS and array portfolio and support efficient and streamlined workflows for cancer research and other applications using Illumina’s NGS sequencers, including the newly launched NextSeq™ 500 sequencing system.

  • TruSeq® RNA Access Library Prep Kits offer a reproducible, economical solution for analyzing RNA isolated from formalin-fixed, paraffin-embedded (FFPE) tissues, and other low-quality samples. Starting with as little as 10 ng total RNA, the kits deliver the discovery power of RNA sequencing at a reduced cost by focusing on the coding regions of the transcriptome. The kits will begin shipping this month. In addition, the kits will be available on the NeoPrep TM Library Prep System in 2H 2014.
  • TruSight™ Myeloid Sequencing Panel uses expert-curated content to offer accurate, efficient, and cost-effective identification of somatic mutations in myeloid malignancies. It provides an assessment of 54 critical genes, including tumor suppressor genes and hotspots in oncogenes. This fully integrated DNA-to-data solution offers a streamlined workflow and automated data analysis with somatic variant calling. The panel will begin shipping in Q2 2014.
  • New BaseSpace® Core Apps offer informatics support for the cancer market. The TopHat and Cufflinks Apps, as well as the RNA Express App, are designed to support transcriptome data analysis, including detection of fusion genes critical in cancer research. A Tumor Normal App delivers somatic variant calling of tumor and matched normal whole genome data sets based on the accurate Strelka method. In addition, Illumina is developing apps to analyze data from Illumina’s TruSight Tumor Sequencing Panel and TruSeq Amplicon - Cancer Panel, as well as an exome version of the Tumor Normal App that delivers variants (including copy number variations) based on Nextera® Rapid Capture Enrichment data. The RNA-Seq and Tumor Normal Apps will be available early this month in BaseSpace, and the others will be available later in 2014.

“The adoption of a precision cancer medicine, a clinical paradigm based on genetic assessment of a patient’s cancer, is rapidly occurring,” said Hanlee Ji, an Assistant Professor of Medicine at Stanford University and Senior Associate Director of the Stanford Genome Technology Center. “As a physician-scientist who is actively developing and applying novel sequencing approaches in the clinical oncology setting, Illumina’s NGS systems are instrumental tools. The advances in NGS with improved sequence quality and dramatic reduction in cost will continue to enable progress in oncology and genomic medicine.”

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,253.92 +97.07 0.57%
S&P 500 2,010.72 +9.15 0.46%
NASDAQ 4,593.2790 +31.09 0.68%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs